Please assess the completion status of the following clinical trial:

Trial Title: Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male, age ≥18 years~2. Histologically confirmed castrate refractory metastatic adenocarcinoma of the prostate with progressive disease after surgical castration or during androgen suppression therapy including a GNRH agonist or antagonist and after at least 1 additional anti-hormonal manipulation; and serum testosterone level of \< 50 ng/dL or \< 1.7 nmol/L~   Progression will be confirmed either~  * radiologically or~  * by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at least in a 50% increase over the nadir and a PSA \> 2 ng/mL.~  * An antiandrogen withdrawal response must have been excluded after discontinuation of antiandrogen therapy for at least 6 weeks.~3. Metastatic disease confirmed by imaging~4. ECOG performance status 0 or 1~Key Exclusion Criteria:~1. Previous immunotherapy for PCA (e.g. sipuleucel-T \[Provenge®\], experimental cancer vaccines or ipilimumab \[Yervoy®\]).~2. Treatment with any investigational anticancer agents within 4 weeks prior to first dose of study drug~3. Systemic treatment with immunosuppressive agents~4. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection (upper arms or thighs) preventing the administration of i.d. injections into areas of healthy skin.~5. History of or current autoimmune disorders~6. Primary or secondary immune deficiency.~7. Seropositive for human immunodeficiency virus, hepatitis B virus (except after hepatitis B vaccination) or hepatitis C virus infection.~8. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of stroke or transient ischemic attack, all within 6 months prior to enrolment or severe hypertension according to WHO criteria or uncontrolled hypertension at the time of enrolment (systolic blood pressure ≥ 180 mm Hg)´~9. Previous chemotherapy for metastatic PCA.~10. Previous anti-hormonal treatment with abiraterone or any other investigational anti-hormonal treatment.~11. Cancer-related pain requiring opioid narcotics within 28 days before enrolment or an average pain score of \> 3 on a visual analogue scale.~12. Presence of visceral metastases.~13. History of other malignancies other than PCA over the last 5 years (except basal cell carcinoma of the skin).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CV9104 (Type: ACTIVE_COMPARATOR): CV9104 intradermal injection
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intradermal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).